Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra
Now that the EMA has elbowed Novartis’ application for Xiidra off the table, the reverberations are being felt at Takeda.
The pharma giant noted …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
